Amunix Presents Preclinical Data on Its XPAT T Cell Engager Platform at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
October 07, 2021 09:00 ET
|
Amunix Pharmaceuticals, Inc.
AMX-818, an HER2-targeted T cell engager (TCE), is the lead program in Amunix’s XPAT® (XTENylated Protease-Activated TCE) platform designed to improve the therapeutic index of TCEs for the treatment...
OncoMed Presents Data From Brontictuzumab, Vantictumab and Anti-DLL4/VEGF Bispecific Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
November 09, 2015 08:30 ET
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Nov. 09, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) presented clinical and preclinical data related to three of its clinical-stage programs at the...